Journals | Policy | Permission

Journal of Clinical Medicine Research

Original Article

Volume 1, Number 1, April 2009, pages 24-31

Anti-proliferation Effect of Polypeptide Extracted from Scorpion Venom on Human Prostate Cancer Cells in vitro

Prostate cancer (PCa) is the most invasive and frequently diagnosed malignancy in males in the USA and, at present, is the second leading cause of cancer deaths in North American men [1]. The induction of human PCa has been viewed as a multistage process, involving progression from small, latent carcinomas of low histological grade to large, metastasis carcinomas of higher grade [2-4]. Since the growth and development of PCa is initially androgen-dependent, therefore androgen deprivation has been extensively explored as a strategy for PCa prevention and treatment [4, 5]. While PCa patients treated with androgen-deprivation therapy often have remission within a few years, tumor regrowth occurs, which is largely due to the progression of initially androgen dependent PCa cells to tumor cells that do not depend on androgen for their proliferation [6, 7]. At this stage of the disease, the uncontrolled growth and metastasis potential of malignant cells are extremely aggressive, and unfortunately, the prognosis is death of the patient [6-8]. Hormone refractory prostate cancer (HRPC) remains a challenge in the management of prostate cancer patients. Hence, it would be important to find promising agents against advanced androgen-independent prostate cancer. Chinese medicine which contains many chemical compounds exhibited anti-proliferative effects on cancer cells [9]. Medicinal herbs with anticancer activity have long been used for the treatment or prevention of various human disorders in folk medicine [10-14].

Buthus martensi Karsch (BmK), a species belonging to the Buthidae family, extensively distributed from northwestern China to Mongolia and Korea, is a Chinese herb used for the treatment of various abdominal masses in folk medicine. Polypeptide extract from scorpion venom (PESV), a certain group of polypeptide of 50-60 amino acids extracted from Crude venom of BmK with bioactivities, has been reported to have anti-tumor activity. Our previous results showed that PESV exhibited potent anti-proliferative and apoptosis-induced activity against HUVEC, inhibition of neovascularization, suppression of tumor growth of S180 sarcoma and H22 hepatocelluar carcinoma in mice [15, 16]. In the present study, we tried to look at the effect of PESV on cell proliferation, apoptosis, as well as cell cycle in prostate cancer cells, and further study the possibility of PESV as a potent agent in prevention and/or intervention of human prostate cancer.

Several recent studies by others and us have demonstrated that the cancer preventive and therapeutic efficacy of scorpion venom in different animal tumor models and cell culture systems including prostate, breast, colon and skin cancers [17-23]. Recent studies have begun to elucidate the underlying genetic determinants of the morphologic and biologic characteristics of prostate cancer [24-26]. The molecular and genetic alterations that precede morphological changes and are responsible for tumorigenesis and progression of prostate cancer also include alterations in cell cycle regulators and apoptosis-related proteins causing uncontrolled cancer growth. In general, the progression of cell cycle in eukaryotes is a complex process involving arresting G0 phase, and cell growth involving G1, S and G2/M phases in a step-wise manner [27]. These cell cycle phases receive different growth controlling signals that are integrated and processed for the sequential activation of different members of the cyclin-dependent kinases (CDKs), which are serine/threonine kinases [27-30]. Different CDKs govern different phases of the cell cycle such as G1 by CDK4/CDK6, late G1 to early S by CDK2, and G2/M by p34Cdc2 (CDK1) kinase [27-30]. The kinase activity of CDKs is governed by their regulatory subunits known as cyclins, which form a complex with their catalytic subunit CDKs and are activated at a specific phase of the cell cycle [31-33]. The other important components that control CDK kinase activity are cyclin-dependent kinase inhibitors (CDKIs) Cip1/p21 and Kip1/p27 [31-33]. CDKI is shown to inhibit the kinase activity of CDK-cyclin complexes and thus modulates retinoblastoma (Rb) phosphorylation events, which are essential for various cell cycle transitions [31, 34, 35].

Apoptosis is regulated by several protein families, including the upstream Bcl-2 family (e.g., the anti-apoptotic Bcl-2 and pro-apoptotic Bax) and the downstream caspase family (e.g., caspase-3). The activation of apoptosis is controlled at multiple checkpoints within the cell. Upstream, the pro-apoptotic Bax and anti-apoptotic Bcl-2 are membrane-bound pore-forming proteins that interact through heterodimerization. Together they regulate the mitochondrial transmembrane passage of cytochrome c, which in turn activates caspase proteins. The Bax/Bcl-2 ratio appears more important than the individual Bax or Bcl-2 level in determining a cell's vulnerability to apoptosis; high Bax/Bcl-2 ratios lead to greater apoptotic activity [36].

DU145 cells, derived from a brain metastasis of a prostate cancer patient, were purchased from the Institute of Pharmacy, Chinese Academy of Medical Sciences (Beijing, China) and maintained in medium RPMI 1640 supplemented with 10% fetus bovine serum (FBS) in a humidified atmosphere of 5% CO₂ at 37^oC. Cells were harvested when they were approximately 70% - 80% confluent. Cells were treated with serial concentrations of PESV in the following experiments. Untreated cells were used as controls.

The effect of PESV on the viability of DU145 cells was determined by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) assay. The cells were plated at 2x10⁵ cells per well in 200μL RPMI 1640 containing 0, 10, 20, 40, 80, 100, and 200 mg/mL PESV in a 96-well microtiter plate. Each concentration of PESV was repeated in 10 wells. The cells were incubated for 48 hours at 37^oC in an incubator. Following 24 hours of incubation, MTT reagent (4μL, 5 mg/mL in PBS) was added to each well and incubated for 2 hours. The microtiter plate containing the cells was centrifuged at 1,800 rpm for 5 minutes at 4^oC. The MTT solution was removed from the wells by aspiration and the formazan crystals were dissolved in DMSO (150μL). Absorbance was recorded on a microplate reader at 540 nm wavelength.

Coverslips with adherent cells treated with PESV (40mg/mL) for 48 hours were fixed in 4% paraformaldehyde for 15 minutes at room temperature. Then rinsed in distilled water and incubated with 0.2% Triton X-100 in phosphate buffered saline solution (PBS)-Tween 20 for 30 minutes. DNA fragments were labeled with TUNEL-Enzyme (Boehringer Mannheim). The kit was used according to the manufacturer's instructions, with the addition of incubation in TdT Reaction Buffer for 10 minutes before TUNEL reaction. The coverslips were then incubated in TdT Reaction Mixture for 2 hours at 40-45^oC in humidified chamber, rinsed in stop wash buffer for 10 minutes and PBS-Tween 20 for 3 x 2 min. The reaction was detected by incubating coverslips with Streptavidin-HRP in PBS for 20 minutes at room temperature. Then rinse in PBS-Tween 20 for 3 x 2 min, and incubate sections with DAB solution for 5-10 minutes. Cells were counterstained with hematoxylin.

A Positive signal was defined as the presence of a dark brown staining on nuclei of the neoplastic cells or on apoptotic bodies as morphologically defined. Cells were defined as apoptotic if the whole nuclear area of cells labeled positively. Apoptotic bodies were defined as small, positively labeled, globular bodies in the cytoplasm of the tumor cells that could be found either singly or in groups. The apoptotic index was determined by the percentage of apoptotic cells divided by the number of tumor cells in 400x magnification. A total of at least 1000 neoplastic nuclei were counted based on 10 randomly chosen fields at 400x magnification [37]. Apoptotic cells were identified by TUNEL in conjunction with characteristic morphological changes, such as cell shrinkage, membrane blebbing, and chromatin condensation.

The DU145 cells treated with PESV (40 mg/mL) in complete medium for 48 hours. The cells were trypsinized thereafter, washed twice with cold PBS, and centrifuged. The cell pellet was resuspended in 50 μL cold PBS to which cold methanol (450 μL) was added and the cells were incubated for 1 hour at 4^oC. The cells were centrifuged at 1,100 rpm for 5 minutes, washed twice with cold PBS, suspended in 500 μL PBS, and incubated with 5 μL RNase (20 μg/mL final concentration) for 30 minutes. The cells were chilled over ice for 10 minutes and incubated with propidium iodide (50 μg/mL final concentration) for an additional 30 min in the dark. Cells were then analysed for DNA content using a Becton-Dickinson flow cytometor to determine cell cycle phase.

Coverslips with adherent cells treated with PESV (40mg/mL) for 48 hours were fixed in 4% paraformaldehyde for 15 minutes at room temperature. DU145 cells were subjected to immunohistochemical staining, with standard streptavidinbiotin- peroxidase techniques, with diaminobenzidine as the chromogen. In brief, DU145 cells were quenched for 10 minutes with 3% hydrogen peroxide, preincubated with blocking serum at 1:20 in 2% bovine serum albumin (BSA)/PBS for 15 minutes at room temperature. After incubation with the primary antibodies, slides were rinsed with PBS, and the secondary antibody was applied at 1:500 in PBS for 30 minutes at room temperature. After rinses with PBS for 30 seconds, slides were incubated with streptavidin/peroxidase at 1:500 in PBS for 30 minutes at room temperature, then rinsed with PBS and incubated for 15 minutes in 0.06% diaminobenzidine and counter-stained with hematoxylin. The following antibodies were used for immunohistochemical staining: Bcl-2 (clone: 124,1:40 dilution, incubation for 2 hours; Dako Corp, Carpinteria, CA), Bax (clone: H62, 1:100 dilution, incubation overnight; Santa Cruz Biotechnology, Inc, Santa Cruz, CA), P27/kip1(clone:M197,1:100 dilution, incubation overnight; Santa Cruz Biotechnology, Inc, Santa Cruz, CA), Cyclin E (clone:M-20,1:50 dilution, incubation overnight; Santa Cruz Biotechnology, Inc, Santa Cruz, CA). Replacing the primary antibody by PBS/5%BSA included negative controls.

Immunoreactivity was quantified within 5 random fields at 100x magnification with a Leica DM4000 B system and Leica QWin V3 software was applied to evaluate grey scale intensity variations. In computing, a grayscale or greyscale digital image is an image in which the value of each pixel is a single sample. Displayed images of this sort are typically composed of shades of gray, varying from black at the weakest intensity to white at the strongest. The grey scale intensity and protein expression have inverse relation.

All data are expressed as the mean ± SE. A t test for unpaired or paired data, as appropriate, was used to compare continuous variables between groups. P < 0.05 was considered to indicate statistical significance. All calculations were performed using the SPSS 10.0 statistical package.

We evaluated whether PESV treatment imparts antiproliferative effects in human prostate cancer cells. Employing the MTT assay, we observed that PESV (10- 200 mg/L) treatment on DU145 cells resulted in dose-dependent decrease in the cell growth (Fig. 1).

Click for large image

Figure 1. Effect of PESV on the growth of prostate cancer cells DU145. Cells were treated with PESV (10, 20, 40, 80, 100, and 200mg/L), and the percentage inhibition of cell growth was determined by MTT assay in a 96-well microtiter plate as detailed in Materials and Methods. Columns, mean of three separate experiments wherein each treatment was repeated in 10 wells; bars, SE.

DU145 cells after exposure to PESV were stained by TUNEL. As shown in Fig. 2, apoptotic nuclei and fragmented DNA were stained dark brown in treated cells (Fig. 2b) but not in the untreated controls (Fig. 2a). The apoptotic index is significantly higher in the PESV-treated cells than in the control (Table 1).

Click for large image

Figure 2. Detection of PESV-induced apoptosis on DU145 cells by DNA fragment TUNEL staining. Apoptotic nuclei and fragmented DNA were stained dark brown in treated cells (2b) but not in untreated controls (2a) in DU145 cells. Original magnification x400.

Click to view

Table 1. Effect of PESV on apoptosis in prostate cancer cells DU145 (TUNEL Assay)

Grey Scale Intensity variants of Bax and Bcl-2 immunoreactivity were evaluated by Leica QWin V3 software in DU145 cells treated with PESV and control group. Fig. 3 indicated the inverse relation between the grey scale intensity and protein expression. Higher grey scale intensity stands for weaker protein expression, and lower intensity stands for stronger protein expression. Treatment with PESV resulted in overexpression of Bax in DU145 cells, whereas Bcl-2 expression reduced. In each comparison, there was a significant difference (P < 0.05).

Click for large image

Figure 3. Grey Scale Intensity variants evaluated by Leica QWin V3 software of Bax and Bcl-2 immunoreactivity in DU145 cells treated with PESV and control group. Higher grey scale intensity standing for weaker protein expression, and lower, sronger protein expression. Columns, mean of three separate experiments conducted in triplicate with DU145 cells; bars, SE.

We determined the cell cycle phenotype of DU145 cell line by flow cytometry. As shown in Figure 4, DU145 cells exhibited PESV-associated G1/S arrest occurring at 48 h after exposure to PESV (40 mg/mL). Cells showed a lack of proliferation at 48 h in comparison with untreated controls (not shown), indicating that the PESV (40 mg/mL) caused proliferation arrest. We further detected the expression of cyclerelated protein cyclin E and p27 by immunohistochemical staining. Immunoreactivity was quantified within 5 random fields at 100x magnification. As shown in Fig. 5 and Fig. 6, cyclin E and p27(Kip1) immunostaining pattern was nuclear. DU145 cells exhibited lower expression of cyclin E protein and higher expression of p27(Kip1) protein after exposure to PESV (40 mg/mL) compared with untreated control.

Click for large image

Figure 4. Representative DNA histograms and percentage of cells in different cell cycle phases after incubated with 40mg/L of PESV (B) for 48 h in human DU145 cells by flow cytometry. The growing cells (60% confluent) were treated with PESV (40mg/L) for 48 hours, and the DNA cell cycle analysis was done as described in Materials and Methods. Columns, mean of three separate experiments conducted in triplicate with DU145 cells; bars, SE.

Click for large image

Figure 5. Representative image of cell cycle-related protein expression. P27kip1 (5a, 5b) and Cyclin E (5c, 5d). p27 expressed in the nuclei in DU145 cells treated with PESV (5b) is stonger than the control (5a); But Cyclin E expressed in the nuclei in DU145 cells treated with PESV (5d) is weaker than the control (5c).

Click for large image

Figure 6. Grey Scale Intensity variants evaluated by Leica QWin V3 software of Cyclin E and p27 immunoreactivity in DU145 cells treated with PESV and control group. Higher grey scale intensity standing for weaker protein expression, and lower, sronger protein expression.

The present study investigates the biological effects of PESV, the major biologically active component in crude scorpin venom, on human prostate cancer DU145 cells. The data support the hypothesis that PESV could be an effective chemoprevention/intervention agent for prostate cancer. Our results clearly demonstrate that PESV induces cell cycle arrest and growth inhibition in human prostate cancer cells, and it induces cell apoptosis at 40 mg/mL concentration with apoptosis index (AI) higher than the controls.

The molecular studies reported here demonstrate that PESV strongly induces the protein expression of Kip1/p27, and decreases cyclin E expression, with an increased interaction/binding between CDKIs and CDK which possibly causes an inhibition in the kinase activity of CDKs. These mechanistic observations were in accordance with an overall efficacy of PESV in inducing a G1 arrest in the cell cycle followed by the inhibition of cell growth.

Cell division depends on the activation of cyclin, which binds to CDKs to induce cell cycle progression towards S phase and later to initiate mitosis; uncontrolled CDK kinase activity is one of the major causes of cancer progression as their functions are tightly regulated by CDKIs such as the Cip1/p21 and Kip1/p27 proteins in normal cell cycle progression [38]. Following anti-mitogenic signals or DNA damage, CDKIs (Cip1/p21 and Kip1/p27) bind to the cyclin–CDK complexes to inhibit their catalytic activity and thus inhibit cell cycle progression [38]. The Rb protein, which is involved in the regulation of the transcription factor E2F [41], is a critical determinant for the restriction-point transition during G1 phase [38, 39], as it is phosphorylated during G1 phase initially by CDK4 or CDK6 and is subsequently maintained in this form by CDK2 [40, 41].

The expression level of cyclins is also an important determinant in cell cycle progression particularly during G1/S and G2/M transitions [38]. D-type cyclins have been shown to be important for progression through the G1 phase, where cyclin E is expressed in late G1 that plays an important role in the G1 to S transition [42-45]. The increased protein expression of G1 cyclins in cancer cells has also been shown to be a major factor in driving uncontrolled growth because cancer cells either lack (with undetectable expression) CDKIs or they are non-functional [46]. The increased expression of CDKIs with decreased expression of cyclins and CDKs and decreased CDK kinase activity induced by PESV treatment in human prostate cancer cells suggest that PESV might be effective for the treatment or prevention of prostate cancer.

Apoptosis is regulated by several protein families, including the upstream Bcl-2 family (e.g., the antiapoptotic Bcl-2 and proapoptotic Bax) and the downstream caspase family (e.g., caspase-3). The activation of apoptosis is controlled at multiple checkpoints within the cell. Bcl-2 family members are important regulators of apoptosis that include antiapoptotic (Bcl-2, Bcl-XL and Mcl-1), proapoptotic (Bax and Bak) and the BH3-domain-only (Bim, Bid and Bik) proteins [47]. Molecules belonging to the B-cell lymphoma leukaemia-2 (Bcl-2)/Bax system play a crucial role in the regulation of the apoptotic process. In particular, Bcl-2 is an intracellular protein that inhibits apoptosis while Bax counteracts the anti-apoptotic function of Bcl-2 by binding to this molecule [36]. Upstream, the proapoptotic Bax and antiapoptotic Bcl-2 are membrane-bound pore-forming proteins that interact through heterodimerization. Together, they regulate the mitochondrial transmembrane passage of cytochrome C, which in turn activates caspase proteins. The Bax/Bcl-2 ratio appears more important than the individual Bax or Bcl-2 level in determining a cell's vulnerability to apoptosis; high Bax/Bcl-2 ratios lead to greater apoptotic activity [36]. This study has also shown that PESV induces cell apoptosis in DU145 prostate cancer cells. We conformed that the induction of apoptosis was mediated through Bax overexpression with bcl-2 down regulation.

Cancer develops when the balance between cell proliferation and cell death is disturbed, and the aberrant cell proliferation leads to tumor growth. It is well known that apoptosis and its related signaling pathways have a profound effect on the progression of cancer [48-49], suggesting that agents inducing apoptotic death of human cancer cells may play a critical role in cancer prevention/intervention including prostate cancer. In this regard, whereas there are several classes of chemotherapy drugs causing apoptotic death of cancer cells, their non-selective efficacy (toxicity) in other tissues has been a limitation in their efficacy. Our data demonstrate significant apoptotic death induction by PESV only in prostate cancers, but not in normal prostate epithelial cells, suggesting the possibility of both selectivity and specificity in PESV efficacy against prostate cancer cells.

More studies, however, are needed in the future to support this assumption, and to identify its mechanism of action in modulating mitogenic and survival signaling cascades in human prostate cancer. In addition, the significance of the observations made in the present study need to be established in a broader context by conducting further studies in a variety of cell lines and xenograft animal models of human prostate cancer. The encouraging data suggest that PESV might be a promising agent in adjuvant therapy for prostate cancer.

Acknowledgments

This work was supported by funding from the National Nature Science Foundation of China. No.30371841.

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55(1):10-30.
   pubmed
2. De Marzo AM, Meeker AK, Zha S, Luo J, Nakayama M, Platz EA, Isaacs WB, et al. Human prostate cancer precursors and pathobiology. Urology. 2003;62(5 Suppl 1):55-62.
   pubmed
3. Sakr WA, Partin AW. Histological markers of risk and the role of high-grade prostatic intraepithelial neoplasia. Urology. 2001;57(4 Suppl 1):115-120.
   pubmed
4. Nelson WG, De Marzo AM, Deweese TL, Lin X, Brooks JD, Putzi MJ, Nelson CP, et al. Preneoplastic prostate lesions: an opportunity for prostate cancer prevention. Ann N Y Acad Sci. 2001;952:135-144.
   pubmed
5. Bostwick DG, Qian J. Effect of androgen deprivation therapy on prostatic intraepithelial neoplasia. Urology. 2001;58(2 Suppl 1):91-93.
   pubmed
6. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1(1):34-45.
   pubmed
7. Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am J Pathol. 1998;152(1):1-9.
   pubmed
8. Pilat MJ, Kamradt JM, Pienta KJ. Hormone resistance in prostate cancer. Cancer Metastasis Rev. 1998;17(4):373-381.
   pubmed
9. Kan SF, Yu CH, Pu HF, Hsu JM, Chen MJ, Wang PS. Anti-proliferative effects of evodiamine on human prostate cancer cell lines DU145 and PC3. J Cell Biochem. 2007;101(1):44-56.
   pubmed
10. Amirghofran Z, Bahmani M, Azadmehr A, Javidnia K. Induction of apoptosis in leukemia cell lines by Linum persicum and Euphorbia cheiradenia. J Cancer Res Clin Oncol. 2006;132(7):427-432.
    pubmed
11. Amersi F, Shen XD, Anselmo D, Melinek J, Iyer S, Southard DJ, Katori M, et al. Ex vivo exposure to carbon monoxide prevents hepatic ischemia/reperfusion injury through p38 MAP kinase pathway. Hepatology. 2002;35(4):815-823.
    pubmed
12. Ambrosino G, Varotto S, Basso MM, Galavotri D, Cecchetto A, Carraro P, Naso A, et al. Development of a new bioartificial liver using a porcine autologous biomatrix as hepatocyte support. Asaio J. 2002;48(6):592-597.
    pubmed
13. Kang JX, Liu J, Wang J, He C, Li FP. The extract of huanglian, a medicinal herb, induces cell growth arrest and apoptosis by upregulation of interferon-beta and TNF-alpha in human breast cancer cells. Carcinogenesis. 2005;26(11):1934-1939.
    pubmed
14. Shoemaker M, Hamilton B, Dairkee SH, Cohen I, Campbell MJ. In vitro anticancer activity of twelve Chinese medicinal herbs. Phytother Res. 2005;19(7):649-651.
    pubmed
15. Zhang WD, Cui YZ, Wu LC, Jia Q, Song SQ, Wang ZX, Dong Q. Experimental study of polypeptide exracted from scorpion venom on angiogenesis. Chinese Journal of Cell Biology. 2005;343-346.
16. Zhang WD, Cui YZ, Yao CF, Jia Q, Song SQ, Wang ZX, Dong Q. Polypeptide extract from scorpion venom inhibits angiogenesis and angiogenesis-dependent tumor growth. Chinese Pharmacological Bulletin. 2005;708-711.
17. Wang WX, Ji YH. Scorpion venom induces glioma cell apoptosis in vivo and inhibits glioma tumor growth in vitro. J Neurooncol. 2005;73(1):1-7.
    pubmed
18. Yang JB, Li XW, Dong WH, Kong TH, Song HX, Zheng XY, Liu GT. Effect of anticancer polypeptide from Buthus Martensii venom on immune function in the H22-bearing mice. Zhongguo Zhong Yao Za Zhi. 2000;736-739.
19. Jia L, Meng XX, Sun HD. Studies of Buthus martensii Karsch (BMK) on inhibition of cell growth and induction of apoptosis in leukemic HL-60 cell line. Pharmacology and Clinics of Chinese Materia Medica. 2001;26-28.
20. Yang CX, Dai SM, Zhu L. Effect of polypeptide purified from Buthus martensi kirsch(PBMK) on proliferation and apoptosis in human hepatoma cell line. Cancer Research On Prevention and Treatment. 2002;184-186.
21. Shen DH, Gao CF, Wang YH, Li DH, Wang XL, Wang P. Effect of the Composition of Scorpion Venom Crude (SVC) on Lovo Cells. The Practical Journal of Cancer. 2002;17:339-343.
22. Kong TH, Lin S, Han XF, Ju JH, Dong WH. Inhibitory effect of polypeptide from Buthus martensii Karsch on neoplasm cells. Chinese Journal of Pathophysiology. 2004;20:968-972.
23. Zhang HM, Liu YF, Zhang JH. Advances in antitumor activity of Scorpion. Journal of Shenyang Pharmaceutical University. 2006;23:401-405.
24. Shankar S, Srivastava RK. Involvement of Bcl-2 family members, phosphatidylinositol 3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in prostate cancer. Int J Oncol. 2007;30:905-918.
    pubmed
25. Tam CW, Mo CW, Yao KM, Shiu SY. Signaling mechanisms of melatonin in antiproliferation of hormone-refractory 22Rv1 human prostate cancer cells: implications for prostate cancer chemoprevention. J Pineal Res. 2007;42(2):191-202.
    pubmed
26. Verras M, Lee J, Xue H, Li TH, Wang Y, Sun Z. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res. 2007;67(3):967-975.
    pubmed
27. Agarwal R. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol. 2000;60(8):1051-1059.
    pubmed
28. Meyerson M, Harlow E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol. 1994;14(3):2077-2086.
    pubmed
29. Wesierska-Gadek J, Gueorguieva M, Horky M. Dual action of cyclin-dependent kinase inhibitors: induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin. Pol J Pharmacol. 2003;55(5):895-902.
    pubmed
30. Swanton C. Cell-cycle targeted therapies. Lancet Oncol. 2004;5(1):27-36.
    pubmed
31. Bhatia N, Agarwal R. Detrimental effect of cancer preventive phytochemicals silymarin, genistein and epigallocatechin 3-gallate on epigenetic events in human prostate carcinoma DU145 cells. Prostate. 2001;46(2):98-107.
    pubmed
32. Fischer PM. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors. Curr Opin Drug Discov Devel. 2001;4(5):623-634.
    pubmed
33. Venkateswaran V, Fleshner NE, Klotz LH. Modulation of cell proliferation and cell cycle regulators by vitamin E in human prostate carcinoma cell lines. J Urol. 2002;168(4 Pt 1):1578-1582.
    pubmed
34. Venkateswaran V, Klotz LH, Fleshner NE. Selenium modulation of cell proliferation and cell cycle biomarkers in human prostate carcinoma cell lines. Cancer Res. 2002;62(9):2540-2545.
    pubmed
35. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol. 2000;183(1):10-17.
    pubmed
36. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74(4):609-619.
    pubmed
37. Losa M, Barzaghi RL, Mortini P, Franzin A, Mangili F, Terreni MR, Giovanelli M. Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors : comparison between micro- and macroadenomas. Am J Pathol. 2000;156(1):245-251.
    pubmed
38. Singh RP, Dhanalakshmi S, Agarwal R. Phytochemicals as cell cycle modulators--a less toxic approach in halting human cancers. Cell Cycle. 2002;1(3):156-161.
    pubmed
39. Planas-Silva MD, Weinberg RA. The restriction point and control of cell proliferation. Curr Opin Cell Biol. 1997;9(6):768-772.
    pubmed
40. Connell-Crowley L, Harper JW, Goodrich DW. Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol Biol Cell. 1997;8(2):287-301.
    pubmed
41. Zarkowska T, Mittnacht S. Differential phosphorylation of the retinoblastoma protein by G1/S cyclin-dependent kinases. J Biol Chem. 1997;272(19):12738-12746.
    pubmed
42. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993;7(5):812-821.
    pubmed
43. Lukas J, Pagano M, Staskova Z, Draetta G, Bartek J. Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene. 1994;9(3):707-718.
    pubmed
44. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol. 1995;15(5):2612-2624.
    pubmed
45. Resnitzky D, Reed SI. Different roles for cyclins D1 and E in regulation of the G1-to-S transition. Mol Cell Biol. 1995;15(7):3463-3469.
    pubmed
46. Dulic V, Lees E, Reed SI. Association of human cyclin E with a periodic G1-S phase protein kinase. Science. 1992;257(5078):1958-1961.
    pubmed
47. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004;116(2):205-219.
    pubmed
48. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis. 2000;21(3):485-495.
    pubmed
49. Tyagi A, Agarwal C, Harrison G, Glode LM, Agarwal R. Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis. 2004;25(9):1711-1720.
    pubmed

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Journal of Clinical Medicine Research is published by Elmer Press Inc.